Skip to main content

Advertisement

SpringerLink
Log in

Serotonin and the GI tract

  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Serotonin (5-hydroxytryptamine, 5-HT) participates in several functions of the gastrointestinal tract. Receptors in seven families (5-HT1-5-HT7) were identified, many of which are present on enterocytes, intrinsic and extrinsic neurons, interstitial cells, and gut myocytes. Most 5-HT is released from enterochromaffin cells in response to physiologic and pathologic stimuli. Roles of 5-HT in health include control of normal gut motor activity, secretion, and sensation, and regulation of food intake and cell growth. Abnormalities of serotonergic function contribute to symptom genesis in functional bowel disorders, inflammatory and infectious diseases of the gut, emetic responses to varied stimuli, obesity, and dysregulation of cell growth. Therapies acting as agonists or antagonists of 5-HT receptors or that modulate 5-HT reuptake play prominent roles in managing these conditions, although use of many agents is hampered by cardiopulmonary complications. Novel agents are in testing, which may exhibit efficacy without significant toxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Tonini M: 5-Hydroxytryptamine effect in the gut: the 3, 4 and 7 receptors. Neurogastroenterol Motil 2005, 17:637–642.

    Article  PubMed  CAS  Google Scholar 

  2. Van Lelyveld N, Ter Linde J, Schipper ME, Samsom M: Regional differences in expression of TPH-1, SERT, 5-HT3, and 5-HT4 receptors in the human stomach and duodenum. Neurogastroenterol Motil 2007, 19:342–348.

    Article  PubMed  CAS  Google Scholar 

  3. Holbrook JD, Gill CH, Zebda N, et al.: Characterization of 5-HT3C, 5-HT3D and 5-HT3E receptor subunits: evolution, distribution and function. J Neurochem 2009, 108:384–396.

    Article  PubMed  CAS  Google Scholar 

  4. Gershon MD, Tack J: The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007, 132:397–414.

    Article  PubMed  CAS  Google Scholar 

  5. Kidd M, Modlin IM, Gustafsson BI, et al.: Luminal regulation of normal and neoplastic human EC cell serotonin release is mediated by bile salts, amines, tastants, and olfactants. Am J Physiol Gastrointest Liver Physiol 2008, 295:G260–G272.

    Article  PubMed  CAS  Google Scholar 

  6. Chen JJ, Li ZS, Pan H, et al.: Maintenance of serotonin in the intestinal mucosa and ganglia of mice that lack the high-affinity serotonin transporter: abnormal intestinal motility and the expression of cation transporters. J Neurosci 2001, 21:6348–6361.

    PubMed  CAS  Google Scholar 

  7. Tack J, Vanden Berghe P, Coulie B, et al.: Sumatriptan is an agonist at 5-HT1P receptors on myenteric neurons in the guinea pig gastric antrum. Neurogastroenterol Motil 2007, 19:39–46.

    Article  PubMed  CAS  Google Scholar 

  8. Bjornsson ES, Chey WD, Hooper F, et al.: Impaired gastrocolonic response and peristaltic reflex in slow transit constipation: role of 5-HT3 pathways. Am J Physiol 2002, 283:G400–G407.

    CAS  Google Scholar 

  9. Camilleri M, Atanasova E, Carlson PJ, et al.: Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 2002, 123:425–432.

    Article  PubMed  CAS  Google Scholar 

  10. Berman SM, Chang L, Suyenobu B, et al.: Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist alosetron. Gastroenterology 2002, 123:969–977.

    Article  PubMed  CAS  Google Scholar 

  11. Sabate JM, Bouhassira D, Poupardin C, et al.: Sensory signalling effects of tegaserod in patients with irritable bowel syndrome with constipation. Neurogastroenterol Motil 2008, 20:134–141.

    PubMed  CAS  Google Scholar 

  12. Beattie DT, Smith JA: Serotonin pharmacology in the gastrointestinal tract: a review. Naunyn Schmiedebergs Arch Pharmacol 2008, 377:181–203.

    Article  PubMed  CAS  Google Scholar 

  13. Gwynne RM, Ellis M, Sjovall H, Bornstein JC: Cholera toxin induces sustained hyperexcitability in submucosal secretomotor neurons in guinea pig jejunum. Gastroenterology 2009, 136:299–308.

    Article  PubMed  Google Scholar 

  14. Hirata T, Keto Y, Nakata M, et al.: Effects of serotonin 5-HT3 receptor antagonists on CRF-induced abnormal colonic water transport and defecation in rats. Eur J Pharmacol 2008, 587:281–284.

    Article  PubMed  CAS  Google Scholar 

  15. Garfield AS, Heisler LK: Pharmacological targeting of the serotonergic system for the treatment of obesity. J Physiol 2009, 587:49–60.

    Article  PubMed  CAS  Google Scholar 

  16. Halford JC, Harrold JA, Boyland EJ, et al.: Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs 2007, 67:27–55.

    Article  PubMed  CAS  Google Scholar 

  17. Bouwknecht JA, van der Gugten J, Hijzen TH, et al.: Male and female 5-HT1B receptor knockout mice have higher body weights than wildtypes. Physiol Behav 2001, 74:507–516.

    Article  PubMed  CAS  Google Scholar 

  18. Woolley ML, Bentley JC, Sleight AJ, et al.: A role for 5-HT6 receptors in retention of spatial learning in the Morris water maze. Neuropharmacology 2001, 41:210–219.

    Article  PubMed  CAS  Google Scholar 

  19. Nakamura K, Sato T, Ohashi A, et al.: Role of a serotonin precursor in development of gut microvilli. Am J Pathol 2008, 172:333–344.

    Article  PubMed  CAS  Google Scholar 

  20. Yadav VK, Ryu JH, Suda N, et al.: Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 2008, 135:825–837.

    Article  PubMed  CAS  Google Scholar 

  21. Wouters MM, Gibbons SJ, Roeder JL, et al.: Exogenous serotonin regulates proliferation of interstitial cells of Cajal in mouse jejunum through 5-HT2B receptors. Gastroenterology 2007, 133:897–906.

    Article  PubMed  CAS  Google Scholar 

  22. Coates MD, Mahoney CR, Linden DR, et al.: Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004, 126:1657–1664.

    Article  PubMed  CAS  Google Scholar 

  23. Coleman N, Foley S, Dunlop SP, et al.: Abnormalities of serotonin metabolism and its relation to symptoms in untreated celiac disease. Clin Gastroenterol Hepatol 2006, 4:874–881.

    Article  PubMed  CAS  Google Scholar 

  24. Costedio MM, Coates MD, Danielson AB, et al.: Serotonin signaling in diverticular disease. J Gastrointest Surg 2008, 12:1439–1445.

    Article  PubMed  Google Scholar 

  25. Wang H, Steeds J, Motomura Y, et al.: CD4+ T cell-mediated immunological control of enterochromaffin cell hyperplasia and 5-hydroxytryptamine production in enteric infection. Gut 2007, 56:949–957.

    Article  PubMed  CAS  Google Scholar 

  26. Dunlop SP, Coleman NS, Blackshaw E, et al.: Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005, 3:349–357.

    Article  PubMed  CAS  Google Scholar 

  27. Van Lelyveld N, Ter Linde J, Schipper M, Samsom M: Serotonergic signaling in the stomach and duodenum of patients with gastroparesis. Neurogastroenterol Motil 2008, 20:448–455.

    Article  PubMed  CAS  Google Scholar 

  28. Van Kerkhoven LA, Laheij RJ, Jansen JB: Meta-analysis: a functional polymorphism in the serotonin transporter gene encoding for activity of the serotonin transporter protein is not associated with the irritable bowel syndrome. Aliment Pharmacol Ther 2007, 26:979–986.

    Article  PubMed  CAS  Google Scholar 

  29. Kapeller J, Houghton LA, Monnikes H, et al.: First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome. Hum Molec Gen 2008, 17:2967–2977.

    Article  CAS  Google Scholar 

  30. Carmani NA, Crim JL, Janoyan JJ, et al.: A re-evaluation of the neurotransmitter basis of chemotherapy-induced immediate and delayed vomiting: evidence from the least shrew. Brain Res 2009, 1248:40–58.

    Article  CAS  Google Scholar 

  31. Nocito A, Dahm F, Jochum W, et al.: Serotonin regulates macrophage-mediated angiogenesis in a mouse model of colon cancer allografts. Cancer Res 2008, 68:5152–5158.

    Article  PubMed  CAS  Google Scholar 

  32. Andresen V, Montori VM, Keller J, et al.: Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol 2008, 6:545–555.

    Article  PubMed  CAS  Google Scholar 

  33. Chang L, Chey W, Harris L, et al.: Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol 2006, 101:1069–1079.

    Article  PubMed  Google Scholar 

  34. Camilleri M: Is there an experimental basis for the development of ischaemic colitis as a result of 5-HT3 antagonist treatment? Neurogastroenterol Motil 2007, 19:77–84.

    Article  PubMed  CAS  Google Scholar 

  35. De Maeyer JH, Lefebvre RA, Schuurkes JA: 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil 2008, 20:99–112.

    PubMed  Google Scholar 

  36. Li Y, Nie Y, Xie J, et al.: The association of serotonin transporter genetic polymorphisms and irritable bowel syndrome and its influence of tegaserod treatment in Chinese patients. Dig Dis Sci 2007, 52:2942–2949.

    Article  PubMed  CAS  Google Scholar 

  37. Pasricha PJ: Desperately seeking serotonin. A commentary on the withdrawal of tegaserod and the state of drug development for functional and motility disorders. Gastroenterology 2007, 132:2287–2290.

    Article  PubMed  Google Scholar 

  38. Camilleri M, Kerstens R, Rykx A, Vandeplassche l: A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008, 358:2344–2354.

    Article  PubMed  CAS  Google Scholar 

  39. Spiller RC, Meyers NL, Hickling RI: Identification of patients with non-D, non-C irritable bowel syndrome and treatment with renzapride: an exploratory, multicenter, randomized, double-blind, placebo-controlled trial. Dig Dis Sci 2008, 53:3191–3200.

    Article  PubMed  CAS  Google Scholar 

  40. Kim HS, Choi EJ, Park H: The effect of mosapride citrate on proximal and distal colonic motor function in the guinea-pig in vitro. Neurogastroenterol Motil 2008, 20:169–176.

    Article  PubMed  CAS  Google Scholar 

  41. Evangelista S: Drug evaluation: pumosetrag for the treatment of irritable bowel syndrome and gastroesophageal reflux disease. Curr Opin Invest Drugs 2007, 8:416–422.

    CAS  Google Scholar 

  42. Vera-Portocarrero LP, Ossipov MH, King T, Porreca F: Reversal of inflammatory and noninflammatory visceral pain by central or peripheral actions of sumatriptan. Gastroenterology 2008, 135:1369–1378.

    Article  PubMed  CAS  Google Scholar 

  43. Tack J, Broekaert D, Fischler B, et al.: A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 2006, 55:1095–1103.

    Article  PubMed  CAS  Google Scholar 

  44. Halpert A, Dalton CB, Diamant NE, et al.: Clinical response to tricyclic antidepressants in functional bowel disorders is not related to dosage. Am J Gastroenterol 2005, 100:664–671.

    Article  PubMed  CAS  Google Scholar 

  45. Jordan K, Schmoll HJ, Aapro MS: Comparative activity of antiemetic drugs. Crit Rev Oncol Hematol 2007, 61:162–175.

    Article  PubMed  Google Scholar 

  46. Smith BM, Thomsen WJ, Grottick AJ: The potential use of selective 5-HT2C agonists in treating obesity. Expert Opin Invest Drugs 2006, 15:257–266.

    Article  CAS  Google Scholar 

  47. Heal DJ, Smith SL, Fisas A, et al.: Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharm Ther 2008, 117:207–231.

    Article  CAS  Google Scholar 

  48. Xu W, Tanim H, Shapiro S, et al.: Use of antidepressants and risk of colorectal cancer: a nested case-control study. Lancet Oncol 2006, 7:301–308.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology, University of Michigan Health System, 3912 Taubman Center, 5362, Ann Arbor, MI, 48109, USA

    William L. Hasler

Authors
  1. William L. Hasler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William L. Hasler.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hasler, W.L. Serotonin and the GI tract. Curr Gastroenterol Rep 11, 383–391 (2009). https://doi.org/10.1007/s11894-009-0058-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-009-0058-7

Keywords

Search

Navigation